Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement
- Design
- Pharmacovigilance · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had obesity/overweight (age/BMI not reported in abstract).
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 4[Auto] Hypothesis-generating design (auto-provisional).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; last sentences of abstract] We also outline a European research and implementation agenda focused on real-world evidence, harmonised monitoring, workforce development, pharmacovigilance, and equitable access. The challenge is no longer whether incretin-based therapies should be used, but how they should be implemented responsibly within comprehensive obesity care pathways.
01Findings
What the study reported
- Drugs
- Class unspecified
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
Study quality details
- Study design
- Pharmacovigilance analysis
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- not extracted
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- Novo Nordisk, Eli Lilly, Lilly, Boehringer Ingelheim, Amgen, Pfizer, Roche
- Sponsor role
- not reported in abstract
- Author conflicts
- JCC reports honoraria from Novo Nordisk and Eli Lilly, with payments made to his institution, and support from Novo Nordisk for travel and congress registration. JLB reports consulting fees and honoraria from Novo Nordisk, with payments made to her institution, and serves as President-Elect and Trustee of the European Association for the Study of Obesity (EASO), without remuneration. EB declares no financial competing interests and serves as an EASO Trustee and Chair of a WHO Technical Advisory Group. LB reports consulting relationships with Novo Nordisk, Eli Lilly, Amgen, Boehringer Ingelheim, Recordati, Pfizer, and Roche, and honoraria from Rhythm. LF reports honoraria from Eli Lilly, Novo Nordisk, Zentiva, and Boehringer Ingelheim; participation on advisory boards for Eli Lilly, Novo Nordisk, and Boehringer Ingelheim; and unpaid leadership roles as President of the Slovak Obesity Association, EASO Vice President, Chair of the Obesitology Section of the Slovak Diabetes Society, and member of the Slovak Atherosclerosis Society. TH reports travel support from EASO to attend professional and scientific meetings in connection with his role as an EASO Trustee and serves as an EASO Trustee. PS reports consulting fees from Boehringer Ingelheim, Chiesi, Eli Lilly, Novo Nordisk, Roche, and Theras, and honoraria from Chiesi, Eli Lilly, Novo Nordisk, and Theras; all payments were made directly to him. EW declares no competing interests. VY serves as President and Trustee of EASO. ZP d
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Incretin-based therapies have transformed obesity treatment, producing substantial weight loss and benefits across cardiometabolic outcomes. However, translating therapeutic efficacy into sustainable population-level benefit remains challenging across European healthcare systems that vary in workforce capability, multidisciplinary care, reimbursement, access, and monitoring infrastructure. We describe this mismatch as the EASO Integration Paradox: therapeutic innovation has advanced more rapidly than the health-system structures required for its optimal, equitable, and sustainable implementation. In this EASO Position Statement, we propose the EASO Integration Framework, a model for integrating incretin-based therapies into comprehensive obesity care. The framework is organized around five interdependent pillars: Right Patient, Right Care, Right Workforce, Right Data, and Right Access. We also outline a European research and implementation agenda focused on real-world evidence, harmonised monitoring, workforce development, pharmacovigilance, and equitable access. The challenge is no longer whether incretin-based therapies should be used, but how they should be implemented responsibly within comprehensive obesity care pathways.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 20, 2026 | 42733510 first ingestion |